肝転移治療市場規模、シェア、動向分析レポート：治療タイプ別、原発がん別、流通チャネル別、地域別、セグメント予測、2024年～2030年

肝転移治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の肝転移治療市場は2030年までに26億6,000万米ドルに達し、2024年から2030年までのCAGRは7.3％で拡大する見込みです。

対象疾患の有病率の上昇、発展途上国におけるがんの進行期診断、製品承認数の増加が業界の成長を促進すると予想されています。

大腸がん、乳がん、肺がんは、肝臓に転移する主要なタイプのいくつかです。大腸がんの罹患率は2020年の188万人から2030年には245万人に増加すると予想されています。一方、乳がんの罹患率は2020年の226万人から2030年には274万人に増加すると予想されています。これらの主要適応症の罹患率の上昇は、市場の成長を促進すると予想されます。

中低所得国のがん患者の大半は、治療オプションの利用可能性が低い進行段階で診断されます。早期診断法が利用できないことと、診断薬に対する不透明な償還シナリオが診断遅延の主な理由です。診断の進行期／転移期は、この分野に有利な成長機会をもたらします。

一方、特に発展途上国やLMICSでは、がんが進行した段階で診断されても、製品や適切な償還が得られないため、そのような進行段階での治療率は著しく低いです。このような要因が市場の成長を抑制すると予想されます。

肝転移治療市場のレポートハイライト

• 治療タイプ別では、従来の化学療法よりも高い価格で承認された薬剤が存在する標的療法分野が56.52%のシェアで市場を独占しました。
• 2023年には、大腸がんが40.55%のシェアで肝転移治療市場を独占しました。大腸がんの約25～30％が肝臓に転移します。CCLMに対する様々な治療オプションが利用可能であることが、このセグメントの優位性をさらに高めています。
• 流通チャネル別では、2023年に60.07％のシェアを持つ病院薬局セグメントが市場を独占しました。肝転移治療のための入院率が高いことが、このセグメント優位の主な要因の1つです。
• 地域別では、北米が2023年の世界肝転移治療市場で高い収益シェアを占めています。しかし、アジア太平洋は予測期間中に最も急成長する地域となる見込みです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肝転移治療の市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
• 治療タイプの普及と成長の見通しマッピング、2023年
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 市場分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • 業界分析：PESTEL

第4章 肝転移治療市場：治療タイプ別セグメント分析、2018年～2030年（百万米ドル）

• 肝転移治療市場：治療タイプの変動分析

第5章 肝転移治療市場：原発がん別セグメント分析、2018年～2030年（百万米ドル）

• 肝転移治療市場：原発がんの変動分析

第6章 肝転移治療市場：販売チャネル別セグメント分析、2018年～2030年（百万米ドル）

• 肝転移治療市場：流通チャネルの変動分析

第7章 肝転移治療市場：タイプ別、製品別、およびアプリケーション別の地域推定・動向分析

• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東およびアフリカ（MEA）

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
  • New product launch
  • Merger and acquisition
  • Licensing agreements
  • Conferences and campaigns
• 企業の分類
  • イノベーター
  • 市場のリーダー
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
• 公開会社
  • 主要企業の市場シェア分析、2023年
  • 企業の市況分析
  • ヒートマップ分析
  • 競合ダッシュボード分析
• 非公開会社
  • 主要な新興企業のリスト
  • 地域ネットワークマップ
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Bayer AG
  • Eli Lilly and Company
  • Ono Pharmaceutical
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Liver Metastases Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 6 Global Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 7 Global Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 10 North America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 11 North America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 14 U.S. Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 16 Canada Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 17 Canada Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Europe Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 20 Europe Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 21 Europe Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Germany Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 23 Germany Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 24 Germany Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 UK Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 26 UK Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 27 UK Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 France Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 29 France Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 30 France Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Italy Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 32 Italy Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 33 Italy Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Spain Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 35 Spain Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 36 Spain Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Denmark Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 38 Denmark Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 39 Denmark Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Sweden Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 41 Sweden Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 42 Sweden Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Norway Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 44 Norway Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 45 Norway Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Japan Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 51 Japan Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 52 Japan Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 China Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 54 China Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 55 China Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 India Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 57 India Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 58 India Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 South Korea Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 60 South Korea Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 61 South Korea Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Australia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 63 Australia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 64 Australia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Thailand Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 66 Thailand Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 67 Thailand Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Latin America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Latin America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 70 Latin America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 71 Latin America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 Brazil Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 73 Brazil Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 74 Brazil Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 Mexico Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 76 Mexico Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 77 Mexico Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 78 Argentina Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 79 Argentina Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 80 Argentina Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 South Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 89 South Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 90 South Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 91 UAE Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 92 UAE Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 93 UAE Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Kuwait Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 95 Kuwait Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
• Table 96 Kuwait Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Liver Metastases Treatment Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Information Procurement
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 QFD Modeling For Market Share Assessment
• Fig. 8 Market Formulation & Validation
• Fig. 9 Market Snapshot
• Fig. 10 Segment Snapshot (By Treatment Type, By Primary Cancer, And By Distribution Channel)
• Fig. 11 Competitive Landscape Snapshot
• Fig. 12 Penetration & Growth Prospect Mapping For Type, 2023
• Fig. 13 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 14 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 15 Liver Metastases Treatment Market: Treatment Type Outlook And Key Takeaways
• Fig. 16 Liver Metastases Treatment Market: Treatment Type Movement Analysis
• Fig. 17 Chemotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 18 Targeted Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 19 Immunotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 20 Liver Metastases Treatment Market: Primary Cancer Outlook And Key Takeaways
• Fig. 21 Liver Metastases Treatment Market: Primary Cancer Movement Analysis
• Fig. 22 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 23 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 24 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 25 Liver Metastases Treatment Market: Distribution Channel Outlook And Key Takeaways
• Fig. 26 Liver Metastases Treatment Market: Distribution Channel Movement Analysis
• Fig. 27 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 28 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 29 Regional Marketplace: Key Takeaways
• Fig. 30 North America: SWOT Analysis
• Fig. 31 North America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Key Country Dynamics
• Fig. 33 U.S. Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 34 U.S. Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Canada Key Country Dynamics
• Fig. 36 Canada Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 37 Canada Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe: SWOT Analysis
• Fig. 39 Europe Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany Key Country Dynamics
• Fig. 41 Germany Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 42 Germany Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 UK Key Country Dynamics
• Fig. 44 UK Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 45 UK Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 France Key Country Dynamics
• Fig. 47 France Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 48 France Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Italy Key Country Dynamics
• Fig. 50 Italy Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 51 Italy Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Spain Key Country Dynamics
• Fig. 53 Spain Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 54 Spain Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Denmark Key Country Dynamics
• Fig. 56 Denmark Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 57 Denmark Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Sweden Key Country Dynamics
• Fig. 59 Sweden Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 60 Sweden Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Norway Key Country Dynamics
• Fig. 62 Norway Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 63 Norway Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Asia Pacific: SWOT Analysis
• Fig. 65 Asia Pacific Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Japan Key Country Dynamics
• Fig. 67 Japan Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 68 Japan Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 69 China Key Country Dynamics
• Fig. 70 China Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 71 China Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 72 India Key Country Dynamics
• Fig. 73 India Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 74 India Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Australia Key Country Dynamics
• Fig. 76 Australia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 77 Australia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 78 South Korea Key Country Dynamics
• Fig. 79 South Korea Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 80 South Korea Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Thailand Key Country Dynamics
• Fig. 82 Thailand Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 83 Thailand Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Latin America (LATAM): SWOT Analysis
• Fig. 85 Latin America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Brazil Key Country Dynamics
• Fig. 87 Brazil Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 88 Brazil Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Mexico Key Country Dynamics
• Fig. 90 Mexico Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 91 Mexico Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Argentina Key Country Dynamics
• Fig. 93 Argentina Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 94 Argentina Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Middle East & Africa (MEA): SWOT Analysis
• Fig. 96 Middle East & Africa (MEA) Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 97 South Africa Key Country Dynamics
• Fig. 98 Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 99 South Africa Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Saudi Arabia Key Country Dynamics
• Fig. 101 Saudi Arabia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 102 Saudi Arabia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 103 UAE Key Country Dynamics
• Fig. 104 UAE Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 105 UAE Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Kuwait Key Country Dynamics
• Fig. 107 Kuwait Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
• Fig. 108 Kuwait Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Heat Map Analysis
• Fig. 110 Strategic Framework

Liver Metastases Treatment Market Growth & Trends:

The global liver metastases treatment market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.

Colorectal cancer, breast cancer, and lung cancer are some of the key types that metastasize to the liver. The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030. The rising incidence of these primary indications is expected to drive space growth.

Majority of the cancer cases in low and middle-income countries are diagnosed at advanced stages where the availability of therapeutic options is low. The lack of availability of early diagnostics methods combined with uncertain reimbursement scenario for diagnostics are major reasons for delayed diagnosis. The advanced/metastatic stage of diagnosis provide lucrative growth opportunities in this space.

On the other hand, if cancers are diagnosed at advanced stages particularly in developing nations and LMICS, the treatment rate at such advanced stages is significantly less, due to unavailability of products and proper reimbursement. This factor is expected to restrain space growth.

Liver Metastases Treatment Market Report Highlights:

• By treatment type, the targeted therapy segment dominated the market with a share of 56.52% to the presence of approved drugs with a price higher than traditional chemotherapy.
• In 2023, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%. Around 25-30% of all colorectal cancers metastasize to the liver. The availability of various treatment options for CCLM further contributed to the segments' dominance.
• Based on distribution channel, the market was dominated by the hospital pharmacies segment with a share of 60.07% in 2023. The high rate of hospitalization for the treatment of liver metastases is one of the major factors for the dominance of this segment.
• By region, North America has a high revenue share in the global liver metastases treatment market in 2023. However, Asia Pacific is expected to be the fastest growing region during the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Regional scope
  • 1.1.2 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity flow approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
    • 3.1.1.1 Liver cancer treatment market
• 3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2023
• 3.3 Market Dynamics
  • 3.3.1 Market driver analysis
    • 3.3.1.1 Approval of targeted therapy for the treatment of liver metastases
  • 3.3.2 Market restraint analysis
    • 3.3.2.1 Technological advancements for early diagnosis of cancer
• 3.4 Market Analysis Tools
  • 3.4.1 Industry analysis: porter's
    • 3.4.1.1 Threat of new entrants
    • 3.4.1.2 Bargaining power of buyers
    • 3.4.1.3 Competitive rivalry
    • 3.4.1.4 Threat of substitutes
    • 3.4.1.5 Bargaining power of suppliers
  • 3.4.2 Industry analysis: PESTEL
    • 3.4.2.1 Political & Legal
    • 3.4.2.2 Economical
    • 3.4.2.3 Technological

Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)

• 4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
  • 4.1.1 Chemotherapy
    • 4.1.1.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.1.2 Targeted Therapy
    • 4.1.2.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.1.3 Immunotherapy
    • 4.1.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Liver Metastases Treatment Market: Segment Analysis, by Primary Cancer, 2018 - 2030 (USD Million)

• 5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
  • 5.1.1 Colorectal cancer
    • 5.1.1.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD million)
  • 5.1.2 Breast Cancer
    • 5.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
  • 6.1.1 Hospital Pharmacies
    • 6.1.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.1.2 Specialty pharmacies
    • 6.1.2.1 Specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Liver Metastases treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

• 7.1 North America
  • 7.1.1 SWOT analysis
    • 7.1.1.1 North america liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.1.2 U.S.
    • 7.1.2.1 Key country dynamics
    • 7.1.2.2 Target disease prevalence
    • 7.1.2.3 Competitive scenario
    • 7.1.2.4 Regulatory framework
    • 7.1.2.5 Reimbursement scenario
    • 7.1.2.6 U.S. Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.1.3 Canada
    • 7.1.3.1 Key country dynamics
    • 7.1.3.2 Target disease prevalence
    • 7.1.3.3 Competitive scenario
    • 7.1.3.4 Regulatory framework
    • 7.1.3.5 Reimbursement scenario
    • 7.1.3.6 Canada liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.2 Europe
  • 7.2.1 SWOT analysis:
    • 7.2.1.1 Europe liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.2 Germany
    • 7.2.2.1 Key country dynamics
    • 7.2.2.2 Target disease prevalence
    • 7.2.2.3 Competitive scenario
    • 7.2.2.4 Regulatory framework
    • 7.2.2.5 Reimbursement scenario
    • 7.2.2.6 Germany Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.3 UK
    • 7.2.3.1 Key country dynamics
    • 7.2.3.2 Target disease prevalence
    • 7.2.3.3 Competitive scenario
    • 7.2.3.4 Regulatory Framework
    • 7.2.3.5 Reimbursement Scenario
    • 7.2.3.6 UK liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.4 France
    • 7.2.4.1 Key country dynamics
    • 7.2.4.2 Target disease prevalence
    • 7.2.4.3 Competitive scenario
    • 7.2.4.4 Regulatory framework
    • 7.2.4.5 Reimbursement scenario
    • 7.2.4.6 France liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.5 Italy
    • 7.2.5.1 Key country dynamics
    • 7.2.5.2 Target disease prevalence
    • 7.2.5.3 Competitive scenario
    • 7.2.5.4 Regulatory framework
    • 7.2.5.5 Reimbursement scenario
    • 7.2.5.6 Italy liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.6 Spain
    • 7.2.6.1 Key country dynamics
    • 7.2.6.2 Target disease prevalence
    • 7.2.6.3 Competitive scenario
    • 7.2.6.4 Regulatory framework
    • 7.2.6.5 Reimbursement scenario
    • 7.2.6.6 Spain liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.7 Denmark
    • 7.2.7.1 Key country dynamics
    • 7.2.7.2 Target disease prevalence
    • 7.2.7.3 Competitive scenario
    • 7.2.7.4 Regulatory framework
    • 7.2.7.5 Reimbursement scenario
    • 7.2.7.6 Denmark liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.8 Sweden
    • 7.2.8.1 Key country dynamics
    • 7.2.8.2 Target disease prevalence
    • 7.2.8.3 Competitive scenario
    • 7.2.8.4 Regulatory framework
    • 7.2.8.5 Reimbursement scenario
    • 7.2.8.6 Sweden liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.9 Norway
    • 7.2.9.1 Key country dynamics
    • 7.2.9.2 Target disease prevalence
    • 7.2.9.3 Competitive scenario
    • 7.2.9.4 Regulatory framework
    • 7.2.9.5 Reimbursement scenario
    • 7.2.9.6 Norway liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.3 Asia Pacific
  • 7.3.1 SWOT analysis:
    • 7.3.1.1 Asia Pacific liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.2 Japan
    • 7.3.2.1 Key country dynamics
    • 7.3.2.2 Target disease prevalence
    • 7.3.2.3 Competitive scenario
    • 7.3.2.4 Regulatory framework
    • 7.3.2.5 Reimbursement scenario
    • 7.3.2.6 Japan liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.3 China
    • 7.3.3.1 Key country dynamics
    • 7.3.3.2 Target disease prevalence
    • 7.3.3.3 Competitive scenario
    • 7.3.3.4 Regulatory framework
    • 7.3.3.5 Reimbursement scenario
    • 7.3.3.6 China liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.4 India
    • 7.3.4.1 Key country dynamics
    • 7.3.4.2 Target disease prevalence
    • 7.3.4.3 Competitive scenario
    • 7.3.4.4 Regulatory framework
    • 7.3.4.5 Reimbursement scenario
    • 7.3.4.6 India liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.5 Australia
    • 7.3.5.1 Key country dynamics
    • 7.3.5.2 Target disease prevalence
    • 7.3.5.3 Competitive scenario
    • 7.3.5.4 Regulatory framework & reimbursement scenario
    • 7.3.5.5 Australia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.6 Thailand
    • 7.3.6.1 Key country dynamics
    • 7.3.6.2 Target disease prevalence
    • 7.3.6.3 Competitive scenario
    • 7.3.6.4 Regulatory framework & reimbursement scenario
    • 7.3.6.5 Thailand liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.7 South Korea
    • 7.3.7.1 Key country dynamics
    • 7.3.7.2 Target disease prevalence
    • 7.3.7.3 Competitive scenario
    • 7.3.7.4 Regulatory framework & reimbursement scenario
    • 7.3.7.5 South Korea liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.4 Latin America
  • 7.4.1 SWOT analysis:
    • 7.4.1.1 Latin America liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.2 Brazil
    • 7.4.2.1 Key country dynamics
    • 7.4.2.2 Target disease prevalence
    • 7.4.2.3 Competitive scenario
    • 7.4.2.4 Regulatory framework
    • 7.4.2.5 Reimbursement scenario
    • 7.4.2.6 Brazil liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.3 Mexico
    • 7.4.3.1 Key country dynamics
    • 7.4.3.2 Target disease prevalence
    • 7.4.3.3 Competitive scenario
    • 7.4.3.4 Regulatory framework
    • 7.4.3.5 Reimbursement scenario
    • 7.4.3.6 Mexico liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.4 Argentina
    • 7.4.4.1 Key country dynamics
    • 7.4.4.2 Target disease prevalence
    • 7.4.4.3 Competitive scenario
    • 7.4.4.4 Regulatory framework
    • 7.4.4.5 Reimbursement scenario
    • 7.4.4.6 Argentina liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.5 Middle East & Africa (MEA)
  • 7.5.1 SWOT analysis:
    • 7.5.1.1 Middle East & Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.2 South Africa
    • 7.5.2.1 Key Country dynamics
    • 7.5.2.2 Target disease prevalence
    • 7.5.2.3 Competitive scenario
    • 7.5.2.4 Regulatory framework
    • 7.5.2.5 Reimbursement scenario
    • 7.5.2.6 South Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.3 Saudi Arabia
    • 7.5.3.1 Key country dynamics
    • 7.5.3.2 Target disease prevalence
    • 7.5.3.3 Competitive scenario
    • 7.5.3.4 Regulatory framework
    • 7.5.3.5 Reimbursement scenario
    • 7.5.3.6 Saudi Arabia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.4 UAE
    • 7.5.4.1 Key country dynamics
    • 7.5.4.2 Target disease prevalence
    • 7.5.4.3 Competitive scenario
    • 7.5.4.4 Regulatory framework
    • 7.5.4.5 Reimbursement scenario
    • 7.5.4.6 UAE liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.5 Kuwait
    • 7.5.5.1 Key country dynamics
    • 7.5.5.2 Target disease prevalence
    • 7.5.5.3 Competitive scenario
    • 7.5.5.4 Regulatory framework
    • 7.5.5.5 Reimbursement Scenario
    • 7.5.5.6 Kuwait liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.5.7 Rest of MEA liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)

Chapter 8 Competitive Landscape

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 New product launch
  • 8.1.2 Merger and acquisition
  • 8.1.3 Licensing agreements
  • 8.1.4 Conferences and campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market leaders
• 8.3 Vendor Landscape
  • 8.3.1 List of key distributors and channel partners
  • 8.3.2 Key customers
• 8.4 Public Companies
  • 8.4.1 Key company market share analysis, 2023
  • 8.4.2 Company market position analysis
  • 8.4.3 Heat map analysis
  • 8.4.4 Competitive dashboard analysis
    • 8.4.4.1 Market differentiators
• 8.5 Private Companies
  • 8.5.1 List of key emerging companies
  • 8.5.2 Regional network map
• 8.6 Company Profiles
  • 8.6.1. F. Hoffmann-La Roche Ltd.
    • 8.6.1.1 Company overview
    • 8.6.1.2 Financial performance
    • 8.6.1.3 Product benchmarking
    • 8.6.1.4 Strategic initiatives
  • 8.6.2 AstraZeneca
    • 8.6.2.1 Company overview
    • 8.6.2.2 Financial performance
    • 8.6.2.3 Product benchmarking
    • 8.6.2.4 Strategic initiatives
  • 8.6.3 Bayer AG
    • 8.6.3.1 Company overview
    • 8.6.3.2 Financial performance
    • 8.6.3.3 Product benchmarking
    • 8.6.3.4 Strategic initiatives
  • 8.6.4 Eli Lilly and Company
    • 8.6.4.1 Company overview
    • 8.6.4.2 Financial performance
    • 8.6.4.3 Product benchmarking
    • 8.6.4.4 Strategic initiatives
  • 8.6.5 Ono Pharmaceutical
    • 8.6.5.1 Company overview
    • 8.6.5.2 Financial performance
    • 8.6.5.3 Product benchmarking
    • 8.6.5.4 Strategic initiatives
  • 8.6.6 Pfizer, Inc.
    • 8.6.6.1 Company overview
    • 8.6.6.2 Financial performance
    • 8.6.6.3 Product benchmarking
    • 8.6.6.4 Strategic initiatives
  • 8.6.7 Bristol-Myers Squibb Company
    • 8.6.7.1 Company overview
    • 8.6.7.2 Financial performance
    • 8.6.7.3 Product benchmarking
    • 8.6.7.4 Strategic initiatives
  • 8.6.8 Cadila Pharmaceuticals Ltd.
    • 8.6.8.1 Company overview
    • 8.6.8.2 Financial performance
    • 8.6.8.3 Product benchmarking
    • 8.6.8.4 Strategic initiatives